Developer docs
API playgroundTry for free, no card

Search company profiles

SunRock

Full company profile

uuid0008oul

Namestring
SunRock
Legal namestring
SunRock Biopharma S.L.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

SunRock Biopharma S.L. is a privately held Spanish biotechnology company founded in 2014 and headquartered at the CSIEB Biopolo Sionlla in Santiago de Compostela. The company develops a pipeline of first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibody formats targeting the chemokine receptor CCR9 and the receptor tyrosine kinase HER3 for oncology and inflammatory diseases. Its product portfolio includes SRB5 (anti-CCR9 monoclonal antibody with enhanced ADCC for inflammatory bowel disease), SRB123 (a CCR9-targeted ADC co-developed with Escugen Biotechnology), SRB17 (a fully human anti-HER3 IgG1 developed with the University of Stuttgart), SRB19 and SRB21 (HER3-EGFR and HER3-HER2 bispecific antibodies), SRB22/EP0017 (a HER3-TRAIL bifunctional fusion protein), SRB1, and SRB2 (CCR9-targeting antibodies for solid tumors). The company has accumulated registered patent rights covering its CCR9 and HER3 antibody platforms and has generated preclinical data demonstrating 90% tumor regression in HNSCC xenograft models and complete regression in platinum-resistant ovarian and pancreatic cancer models.

Short descriptiontext

SunRock Biopharma is a Spain-based preclinical biotech developing first-in-class and best-in-class therapeutic antibodies, ADCs, and bispecifics targeting CCR9 and HER3 for oncology and inflammatory bowel disease, licensing programs to pharmaceutical partners for development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSantiago De Compostela, Spain
HQ citystring
Santiago De Compostela
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic antibody development, antibody drug conjugates, bispecific antibodies, oncology biologics, inflammatory disease therapeutics
Industry5 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Antibody Development (Oncology and Inflammation Biologics R&D)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Agreements
TypeLicensing Royalties
Description

SunRock licenses its antibody programs to pharmaceutical partners after preclinical validation. Partners such as Debiopharm, Ellipses Pharma, and Chime Biologics receive development and commercialization rights in exchange for upfront payments, milestone payments, and royalties.

sunrockbiopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SunRock Biopharma develops first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting the CCR9 and HER3 receptors for oncology and inflammatory bowel disease. The company operates an open innovation model, advancing antibody candidates through preclinical validation before licensing them to pharmaceutical partners (including Ellipses Pharma, Debiopharm, and Escugen Biotechnology) for clinical development, manufacturing, and global commercialization in exchange for upfront payments, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • SRB5 demonstrates 16x higher depletion of CCR9+ T cells compared to reference anti-CCR9 antibody in preclinical studies
+4 more records
Product overview1 text field

SunRock Biopharma is a Spanish biotech company developing a pipeline of first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting validated oncology and inflammatory disease targets. The core platform focuses on CCR9 and HER3 targets. Key products include SRB5 (anti-CCR9 for IBD via ADCC), SRB123 (CCR9-targeted ADC co-developed with Escugen), SRB17 (anti-HER3 mAb), SRB19 (HER3-EGFR bispecific, licensed to Debiopharm), SRB21 (HER3-HER2 bispecific, licensed to Debiopharm), SRB22/EP0017 (HER3-TRAIL fusion protein licensed to Ellipses Pharma), and SRB2 (anti-CCR9 for pancreatic cancer). The company operates an open innovation model, advancing candidates through preclinical stages before licensing to pharmaceutical partners for clinical development.

Product and service8 records
1SRB5
CategoryTherapeutic monoclonal antibody (anti-CCR9)
Description

Best-in-class humanized anti-CCR9 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity designed for selective depletion of pathogenic CCR9+ T cells in inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.

2SRB123
CategoryAntibody-drug conjugate (ADC) targeting CCR9
Description

First-in-class anti-CCR9 antibody-drug conjugate (ADC) co-developed with Escugen Biotechnology using the EZWi-Fit platform, designed to selectively deliver cytotoxic payloads to CCR9+ tumor cells for the treatment of solid tumors including pancreatic, ovarian, and lung cancer.

3SRB17
CategoryTherapeutic monoclonal antibody (anti-HER3)
Description

Best-in-class fully human anti-HER3 IgG1 monoclonal antibody with improved affinity and dual mechanism of action, developed in collaboration with University of Stuttgart, targeting HER3-overexpressing tumors.

4SRB19
CategoryBispecific antibody / ADC (HER3-EGFR)
Description

Tetravalent single-chain diabody-Fc fusion protein (HER3-EGFR bispecific antibody) outperforming cetuximab in head and neck squamous cell carcinoma models; licensed to Debiopharm for development as a HER3-EGFR bispecific ADC (Debio 2512).

5SRB21
CategoryBispecific antibody / ADC (HER3-HER2)
Description

Anti-HER3-HER2 bispecific antibody licensed to Debiopharm for development as a bispecific ADC (Debio 2512).

6SRB22 (EP0017)
CategoryBifunctional fusion protein (HER3:TRAIL)
Description

First-in-class fully human bifunctional HER3:TRAIL fusion protein that selectively targets HER3 and induces tumor cell death via DR4 and DR5 receptors; exclusively licensed to Ellipses Pharma for global development and commercialization in solid tumors (known at Ellipses as EP0017).

7SRB2
CategoryTherapeutic monoclonal antibody (anti-CCR9)
Description

Humanized anti-CCR9 monoclonal antibody demonstrating efficacy in pancreatic ductal adenocarcinoma through ADCC mechanism, achieving complete tumor regression in xenograft models.

8SRB1
CategoryTherapeutic monoclonal antibody (anti-CCR9)
Description

Anti-CCR9 antibody developed for both immune-mediated inflammatory diseases and solid tumors, with clinical data presented at ECCO 2025 for the IBD indication.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierKeyTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-09-01
Description

Strategic collaboration for manufacturing development of anti-CCR9 antibody SRB5. Chime Biologics, a leading global CDMO, provides GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones for IBD indication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-16
Description

Strategic partnership to co-develop SRB123, a first-in-class CCR9-targeted ADC. SunRock contributes proprietary SRB1 antibody; Escugen provides EZWi-Fit® platform with stable linkers and topoisomerase I inhibitor payload for optimized efficacy and safety profile.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

Multi-asset partnership integrating SunRock's HER2/HER3 targeting antibodies with Debiopharm's Multilink™ and AbYlink™ ADC technologies. Debiopharm secured licensing options for HER3-EGFR and HER3-HER2 bispecific ADCs including SRB19 and SRB21. Extended in January 2024 for HER3-EGFR targeting in EGFR mutated cancers.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-09-21
Description

Exclusive global licensing agreement for SRB22 (HER3:TRAIL bifunctional fusion protein, later named EP0017). Ellipses received worldwide rights to develop and commercialize. SunRock continues involvement through service agreement for translational activities and receives milestone payments and royalties if out-licensed.

5University of Stuttgart
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Collaboration on SRB17 development - best-in-class fully human IgG anti-HER3 with improved affinity and dual mechanism of action. University contributed to the binding site characterization that impairs ligand-dependent and allosteric activation of HER3.

sunrockbiopharma.com
6VHIO (Vall d'Hebron Institute of Oncology)
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Consortium partner in OVERCAD project (€1.8M funding) for CCR9-targeted ADC development in ovarian cancer. Also partner in TRADBI project (€1.7M) for HER3 bispecific antibodies in solid tumors. VHIO provides tumor biomarkers expertise and clinical leadership through Dr. Ana Oaknin.

sunrockbiopharma.com
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Consortium partner in IMPANC project (€1.8M funding) for pancreatic cancer treatment. IDIS research groups (ONCOMET, Pathological Anatomy, GITEAD) validate results in patient samples and develop biomarker characterization strategies using liquid biopsy techniques.

8CiMUS (Center for Research in Molecular Medicine and Chronic Diseases)
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Academic partner in USC-SunRock joint unit for cancer and inflammatory disease therapies (€2.73M funding). Professor Mabel Loza coordinates the initiative. Also collaborated on SRB2 pancreatic cancer research published in Molecular Oncology.

sunrockbiopharma.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Extended licensing agreement to develop HER3-EGFR bispecific ADCs for EGFR mutated cancers, building on initial September 2023 partnership. Uses Debiopharm's Multilink™ technology for enhanced drug-to-antibody ratio.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Danish antibody therapeutics pioneer (DARZALEX, DuoBody®, HexaBody® platforms). Operates in the same antibody-discovery and bispecific space as SunRock at much larger scale, with an established licensing model (multiple partnered programs with pharma) — useful as a benchmark for what a mature version of SunRock's playbook can become.

TypeDirect peer
Description

Clinical-stage Canadian biotech developing multifunctional and bispecific antibody therapeutics (Azymetric™, Effi-function™) — directly comparable in modality (bispecifics/ADCs) and licensing-oriented business model. Both companies build differentiated antibody platforms and license assets to larger pharma for clinical development and commercialization.

TypeOthers
Description

Swiss biopharmaceutical group and one of SunRock's core partners (multi-asset HER3 bispecific ADC licensing). Relevant as the licensee of SunRock's SRB19/SRB21 assets and as a comparable European biopharma that invests in differentiated antibody and ADC platforms through in-licensing.

TypeDirect peer
Description

Clinical-stage US biotech developing masked Probody® antibody therapeutics and bispecifics, including HER3-targeted programs in oncology. Comparable in modality (next-generation antibodies, ADCs) and in building a partnered pipeline around a proprietary platform technology.

TypeOthers
Description

London-based clinical-stage oncology group that licensed SRB22/EP0017 from SunRock in 2022. Relevant as the lead licensee of one of SunRock's key assets and as a comparable small-cap oncology company focused on advancing partnered clinical-stage assets.

6Pieris Pharmaceuticals (now Palvella Therapeutics)
TypeDirect peer
Description

European-originated biotech that historically developed Anticalin® protein therapeutics with a similar licensing model — multiple partnered programs with AstraZeneca, Genentech, and others, small headcount, and reliance on upfront/milestone economics. Highly comparable to SunRock's stage and business model.

TypeDirect peer
Description

Clinical-stage US biotech developing antibody-drug conjugates using proprietary payload and linker platforms (Dolasynthen, Immunosynthen). Comparable in ADC focus and in targeting validated oncology indications with platform-derived candidates.

TypeDirect peer
Description

US clinical-stage biotech developing bispecific antibodies and antibody-drug conjugates using DART® and TRIDENT® platforms, including HER3-targeted programs. Comparable in modality (bispecifics, ADCs) and oncology focus, though at a more advanced clinical stage.

TypeDirect peer
Description

Swiss clinical-stage biotech developing DARPin® protein therapeutics with a similar asset-light model — advancing candidates through preclinical/early clinical stages and partnering with larger pharma for development. Comparable in size, European base, and licensing-driven revenue strategy.

TypeEmerging player
Description

Clinical-stage US biotech with a pipeline of bispecific antibodies (CTX-009, CTX-112, CTX-131) targeting oncology. Comparable in bispecific modality and similar stage of clinical advancement, though with a larger US-based operation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SunRock

Therapeutic Antibody Development (Oncology and Inflammation Biologics R&D)sunrockbiopharma.com

SunRock Biopharma is a Spain-based preclinical biotech developing first-in-class and best-in-class therapeutic antibodies, ADCs, and bispecifics targeting CCR9 and HER3 for oncology and inflammatory bowel disease, licensing programs to pharmaceutical partners for development and commercialization.

What SunRock does

SunRock Biopharma S.L. is a privately held Spanish biotechnology company founded in 2014 and headquartered at the CSIEB Biopolo Sionlla in Santiago de Compostela. The company develops a pipeline of first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibody formats targeting the chemokine receptor CCR9 and the receptor tyrosine kinase HER3 for oncology and inflammatory diseases. Its product portfolio includes SRB5 (anti-CCR9 monoclonal antibody with enhanced ADCC for inflammatory bowel disease), SRB123 (a CCR9-targeted ADC co-developed with Escugen Biotechnology), SRB17 (a fully human anti-HER3 IgG1 developed with the University of Stuttgart), SRB19 and SRB21 (HER3-EGFR and HER3-HER2 bispecific antibodies), SRB22/EP0017 (a HER3-TRAIL bifunctional fusion protein), SRB1, and SRB2 (CCR9-targeting antibodies for solid tumors). The company has accumulated registered patent rights covering its CCR9 and HER3 antibody platforms and has generated preclinical data demonstrating 90% tumor regression in HNSCC xenograft models and complete regression in platinum-resistant ovarian and pancreatic cancer models.

SunRock firmographics

Firmographics
Name
SunRock
Legal name
SunRock Biopharma S.L.
Website
https://sunrockbiopharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
SunRock Biopharma is a Spain-based preclinical biotech developing first-in-class and best-in-class therapeutic antibodies, ADCs, and bispecifics targeting CCR9 and HER3 for oncology and inflammatory bowel disease, licensing programs to pharmaceutical partners for development and commercialization.
Ownership category
akta.pro rank

SunRock industry classification

Industry
Product category
Therapeutic Antibody Development (Oncology and Inflammation Biologics R&D)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Therapeutic antibody development
  • Antibody drug conjugates
  • Bispecific antibodies
  • Oncology biologics
  • Inflammatory disease therapeutics

Where SunRock is headquartered

Location

Headquarters

HQ city
Santiago De Compostela
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

SunRock business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Licensing Agreements: SunRock licenses its antibody programs to pharmaceutical partners after preclinical validation. Partners such as Debiopharm, Ellipses Pharma, and Chime Biologics receive development and commercialization rights in exchange for upfront payments, milestone payments, and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

SunRock product offering

Product offering

Core offering

SunRock Biopharma develops first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting the CCR9 and HER3 receptors for oncology and inflammatory bowel disease. The company operates an open innovation model, advancing antibody candidates through preclinical validation before licensing them to pharmaceutical partners (including Ellipses Pharma, Debiopharm, and Escugen Biotechnology) for clinical development, manufacturing, and global commercialization in exchange for upfront payments, milestones, and royalties.

Product overview

SunRock Biopharma is a Spanish biotech company developing a pipeline of first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting validated oncology and inflammatory disease targets. The core platform focuses on CCR9 and HER3 targets. Key products include SRB5 (anti-CCR9 for IBD via ADCC), SRB123 (CCR9-targeted ADC co-developed with Escugen), SRB17 (anti-HER3 mAb), SRB19 (HER3-EGFR bispecific, licensed to Debiopharm), SRB21 (HER3-HER2 bispecific, licensed to Debiopharm), SRB22/EP0017 (HER3-TRAIL fusion protein licensed to Ellipses Pharma), and SRB2 (anti-CCR9 for pancreatic cancer). The company operates an open innovation model, advancing candidates through preclinical stages before licensing to pharmaceutical partners for clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • SRB5 Best-in-class humanized anti-CCR9 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity designed for selective depletion of pathogenic CCR9+ T cells in inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
  • SRB123 First-in-class anti-CCR9 antibody-drug conjugate (ADC) co-developed with Escugen Biotechnology using the EZWi-Fit platform, designed to selectively deliver cytotoxic payloads to CCR9+ tumor cells for the treatment of solid tumors including pancreatic, ovarian, and lung cancer.
  • SRB17 Best-in-class fully human anti-HER3 IgG1 monoclonal antibody with improved affinity and dual mechanism of action, developed in collaboration with University of Stuttgart, targeting HER3-overexpressing tumors.
  • SRB19 Tetravalent single-chain diabody-Fc fusion protein (HER3-EGFR bispecific antibody) outperforming cetuximab in head and neck squamous cell carcinoma models; licensed to Debiopharm for development as a HER3-EGFR bispecific ADC (Debio 2512).
  • SRB21 Anti-HER3-HER2 bispecific antibody licensed to Debiopharm for development as a bispecific ADC (Debio 2512).
  • SRB22 (EP0017) First-in-class fully human bifunctional HER3:TRAIL fusion protein that selectively targets HER3 and induces tumor cell death via DR4 and DR5 receptors; exclusively licensed to Ellipses Pharma for global development and commercialization in solid tumors (known at Ellipses as EP0017).
  • SRB2 Humanized anti-CCR9 monoclonal antibody demonstrating efficacy in pancreatic ductal adenocarcinoma through ADCC mechanism, achieving complete tumor regression in xenograft models.
  • SRB1 Anti-CCR9 antibody developed for both immune-mediated inflammatory diseases and solid tumors, with clinical data presented at ECCO 2025 for the IBD indication.

Quantifiable outcome

  • SRB5 demonstrates 16x higher depletion of CCR9+ T cells compared to reference anti-CCR9 antibody in preclinical studies
  • +4 more outcomes

Companies that use SunRock

Customer profile

Segments3 records

Ideal customer profiles1 record

SunRock technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SunRock partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered key and core.

  • Chime BiologicskeyImplementation/ SI/ Consulting Partner · 1 September 2025Strategic collaboration for manufacturing development of anti-CCR9 antibody SRB5. Chime Biologics, a leading global CDMO, provides GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones for IBD indication.
  • Escugen BiotechnologycoreStrategic or Co-development Partner · 16 June 2025Strategic partnership to co-develop SRB123, a first-in-class CCR9-targeted ADC. SunRock contributes proprietary SRB1 antibody; Escugen provides EZWi-Fit® platform with stable linkers and topoisomerase I inhibitor payload for optimized efficacy and safety profile.
  • DebiopharmcoreStrategic or Co-development Partner · 21 September 2023Multi-asset partnership integrating SunRock's HER2/HER3 targeting antibodies with Debiopharm's Multilink™ and AbYlink™ ADC technologies. Debiopharm secured licensing options for HER3-EGFR and HER3-HER2 bispecific ADCs including SRB19 and SRB21. Extended in January 2024 for HER3-EGFR targeting in EGFR mutated cancers.
  • Ellipses PharmacoreOEM/ Whitelabel/ Licensing Partner · 21 September 2022Exclusive global licensing agreement for SRB22 (HER3:TRAIL bifunctional fusion protein, later named EP0017). Ellipses received worldwide rights to develop and commercialize. SunRock continues involvement through service agreement for translational activities and receives milestone payments and royalties if out-licensed.
  • University of StuttgartkeyStrategic or Co-development PartnerCollaboration on SRB17 development - best-in-class fully human IgG anti-HER3 with improved affinity and dual mechanism of action. University contributed to the binding site characterization that impairs ligand-dependent and allosteric activation of HER3.
  • VHIO (Vall d'Hebron Institute of Oncology)keyStrategic or Co-development PartnerConsortium partner in OVERCAD project (€1.8M funding) for CCR9-targeted ADC development in ovarian cancer. Also partner in TRADBI project (€1.7M) for HER3 bispecific antibodies in solid tumors. VHIO provides tumor biomarkers expertise and clinical leadership through Dr. Ana Oaknin.
  • IDIS (Health Research Institute of Santiago de Compostela)keyStrategic or Co-development PartnerConsortium partner in IMPANC project (€1.8M funding) for pancreatic cancer treatment. IDIS research groups (ONCOMET, Pathological Anatomy, GITEAD) validate results in patient samples and develop biomarker characterization strategies using liquid biopsy techniques.
  • CiMUS (Center for Research in Molecular Medicine and Chronic Diseases)keyStrategic or Co-development PartnerAcademic partner in USC-SunRock joint unit for cancer and inflammatory disease therapies (€2.73M funding). Professor Mabel Loza coordinates the initiative. Also collaborated on SRB2 pancreatic cancer research published in Molecular Oncology.
  • Debiopharm (HER3-EGFR ADC extension)coreOEM/ Whitelabel/ Licensing PartnerExtended licensing agreement to develop HER3-EGFR bispecific ADCs for EGFR mutated cancers, building on initial September 2023 partnership. Uses Debiopharm's Multilink™ technology for enhanced drug-to-antibody ratio.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

SunRock competitors and assessment

Company assessment

Broad incumbents

  • Genmab: Danish antibody therapeutics pioneer (DARZALEX, DuoBody®, HexaBody® platforms). Operates in the same antibody-discovery and bispecific space as SunRock at much larger scale, with an established licensing model (multiple partnered programs with pharma) — useful as a benchmark for what a mature version of SunRock's playbook can become.

Direct peers

  • Zymeworks: Clinical-stage Canadian biotech developing multifunctional and bispecific antibody therapeutics (Azymetric™, Effi-function™) — directly comparable in modality (bispecifics/ADCs) and licensing-oriented business model. Both companies build differentiated antibody platforms and license assets to larger pharma for clinical development and commercialization.
  • CytomX Therapeutics: Clinical-stage US biotech developing masked Probody® antibody therapeutics and bispecifics, including HER3-targeted programs in oncology. Comparable in modality (next-generation antibodies, ADCs) and in building a partnered pipeline around a proprietary platform technology.
  • Pieris Pharmaceuticals (now Palvella Therapeutics): European-originated biotech that historically developed Anticalin® protein therapeutics with a similar licensing model — multiple partnered programs with AstraZeneca, Genentech, and others, small headcount, and reliance on upfront/milestone economics. Highly comparable to SunRock's stage and business model.
  • Mersana Therapeutics: Clinical-stage US biotech developing antibody-drug conjugates using proprietary payload and linker platforms (Dolasynthen, Immunosynthen). Comparable in ADC focus and in targeting validated oncology indications with platform-derived candidates.
  • Macrogenics: US clinical-stage biotech developing bispecific antibodies and antibody-drug conjugates using DART® and TRIDENT® platforms, including HER3-targeted programs. Comparable in modality (bispecifics, ADCs) and oncology focus, though at a more advanced clinical stage.
  • Molecular Partners: Swiss clinical-stage biotech developing DARPin® protein therapeutics with a similar asset-light model — advancing candidates through preclinical/early clinical stages and partnering with larger pharma for development. Comparable in size, European base, and licensing-driven revenue strategy.

Others

  • Debiopharm: Swiss biopharmaceutical group and one of SunRock's core partners (multi-asset HER3 bispecific ADC licensing). Relevant as the licensee of SunRock's SRB19/SRB21 assets and as a comparable European biopharma that invests in differentiated antibody and ADC platforms through in-licensing.
  • Ellipses Pharma: London-based clinical-stage oncology group that licensed SRB22/EP0017 from SunRock in 2022. Relevant as the lead licensee of one of SunRock's key assets and as a comparable small-cap oncology company focused on advancing partnered clinical-stage assets.

Emerging players

  • Compass Therapeutics: Clinical-stage US biotech with a pipeline of bispecific antibodies (CTX-009, CTX-112, CTX-131) targeting oncology. Comparable in bispecific modality and similar stage of clinical advancement, though with a larger US-based operation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

SunRock social profiles

Digital presence

SunRock financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SunRock leadership team

Management profile

Number of profiles

Profiles3 records

SunRock funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SunRock M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SunRock

What does SunRock do?

SunRock Biopharma develops first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting the CCR9 and HER3 receptors for oncology and inflammatory bowel disease. The company operates an open innovation model, advancing antibody candidates through preclinical validation before licensing them to pharmaceutical partners (including Ellipses Pharma, Debiopharm, and Escugen Biotechnology) for clinical development, manufacturing, and global commercialization in exchange for upfront payments, milestones, and royalties.

Is SunRock a public or private company?

SunRock is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SunRock founded?

SunRock was founded in 2014. It employs 1 to 10 people.

Where is SunRock based?

SunRock is headquartered in Santiago De Compostela, Spain, in the Europe region.

How does SunRock make money?

One revenue line is on record: licensing Agreements.

Who are SunRock's main competitors?

Genmab is listed as a broad incumbent. Direct peers are Zymeworks, CytomX Therapeutics, Pieris Pharmaceuticals (now Palvella Therapeutics), Mersana Therapeutics, Macrogenics and Molecular Partners. Others are Debiopharm and Ellipses Pharma. Compass Therapeutics is listed as an emerging player.

Does SunRock have an API?

No public API is recorded for SunRock.

What industry is SunRock in?

SunRock's product category is Therapeutic Antibody Development (Oncology and Inflammation Biologics R&D). Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5SunRock Biopharma, a Spanish biotechnology company, and Chime Biologics, a global contract development and manufacturing organization (CDMO) based in China, have announced a strategic collaboration to develop SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease. Chime Biologics will provide its global-standard GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones for the antibody. The collaboration is positioned as a critical step toward clinical validation of SRB5, which has potential applications in Crohn's disease, ulcerative colitis, and potentially in CCR9-expressing tumors.Business Wire BlogSunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5SunRock Biopharma and Chime Biologics announced a strategic collaboration to advance SRB5, a humanized anti-CCR9 monoclonal antibody for inflammatory bowel disease. The partnership leverages Chime's GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones. SRB5 targets CCR9+ cells involved in chronic intestinal inflammation.Business Wire BlogDebiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512Debiopharm licensed SunRock Biopharma's SRB21 bispecific antibody targeting HER3 and HER2, and will develop a new ADC called Debio 2512 using its MultiLINK linker technology. The dual-targeting approach aims to overcome resistance in HER2-driven cancers, with Debiopharm citing its Trifecta approach for fit-for-purpose ADCs.PR NewswireSunRock Biopharma et GenScript ProBio concluent un accord de collaboration pour développer un nouveau programme d'anticorps monoclonauxOn February 21, 2021, GenScript ProBio and SunRock Biopharma announced a collaboration for the development and large-scale GMP manufacturing of SunRock's CCR9 therapeutic antibody candidates targeting aggressive cancers. GenScript ProBio will provide comprehensive services from antibody discovery and cell line development through process development to GMP manufacturing, with regulatory submissions planned to NMPA, FDA, and EMA. SunRock Biopharma aims to begin clinical trials in June 2022, offering new monoclonal antibody treatment options for conditions including T-cell acute lymphoblastic leukemia and pancreatic cancer.PR NewswireSunRock Biopharma und GenScript ProBio schließen ein Kollaborationsabkommen zur Entwicklung eines neuen monoklonalen AntikörperprogrammsOn February 21, 2021, GenScript ProBio and SunRock Biopharma announced a collaboration for the development of a new therapeutic monoclonal antibody program targeting CCR9, which is associated with aggressive cancers. The partnership aims to expedite the preclinical discovery to large-scale GMP manufacturing process for SunRock's CCR9 antibody candidates, with clinical trials expected to begin in June 2022. This collaboration represents a significant step towards innovative antibody therapies for cancers with high unmet clinical needs.PR NewswireSunRock Biopharma y GenScript ProBio desarrollarán un nuevo programa de anticuerpos monoclonalesSunRock Biopharma and GenScript ProBio entered a collaboration agreement on February 21, 2021, to develop monoclonal antibody programs targeting CCR9 for aggressive cancers. GenScript ProBio will provide end-to-end services ranging from preclinical discovery to large-scale GMP manufacturing for SunRock's therapeutic candidates. The companies aim to initiate clinical trials by June 2022 to address unmet medical needs in conditions such as T-cell acute lymphoblastic leukemia and pancreatic cancer.